Melatonin sublingual - iX Biopharma

Drug Profile

Melatonin sublingual - iX Biopharma

Alternative Names: WafeRest

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator iX Biopharma
  • Class Hormones; Sleep disorder therapies; Tryptamines
  • Mechanism of Action Antioxidants; Melatonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Sleep disorders

Most Recent Events

  • 08 Feb 2017 Phase-III clinical trials in Sleep disorders in Singapore (Sublingual) (9214692; iX Biopharma website, April 2017)
  • 08 Feb 2017 iX Biopharma announces intention to submit application for registration to the Therapeutics Goods Administration (TGA) Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top